Top Wall Street Forecasters Revamp Omeros Price Expectations Ahead Of Q4 Earnings

Omeros Corporation OMER will release its fourth-quarter financial results after the closing bell on Monday, March 31.

Analysts expect the Seattle, Washington-based company to report quarterly loss at 78 cents per share, versus a year-ago loss of 69 cents per share, according to data from Benzinga Pro.

On March 21, Omeros issued an update of ongoing Zaltenibart Phase 3 PNH clinical trial program.

Omeros shares gained 4.7% to close at $8.92 on Thursday.

Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.

Let's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period.

  • Needham analyst Serge Belanger reiterated a Hold rating on Jan. 17, 2025. This analyst has an accuracy rate of 68%.
  • Cantor Fitzgerald analyst Olivia Brayer reiterated a Neutral rating on Nov. 14, 2024. This analyst has an accuracy rate of 62%.

Considering buying OMER stock? Here’s what analysts think:

Read This Next:

Photo: Shutterstock

OMER Logo
OMEROmeros Corp
$6.97-2.52%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum
97.85
Price Trend
Short
Medium
Long
Got Questions? Ask
Which analysts' ratings indicate a buy for OMER?
How might the Zaltenibart trial outcomes impact OMER's stock?
What are the implications of increased quarterly losses for OMER's future?
Could OMER's clinical trial progress attract new investors?
What industries could be affected by Omeros' earnings report?
Which pharmaceutical stocks could benefit from Omeros' developments?
How will changes in analyst recommendations impact OMER's price?
What does a hold rating suggest for OMER investors?
How might a 4.7% increase in OMER stock influence market perception?
Are there investment strategies tailored for OMER's earnings report?

This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Market News and Data brought to you by Benzinga APIs
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise

Posted In:
Comments
Loading...